Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Apr;48(4):351-5.
doi: 10.1097/MCG.0000000000000083.

Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis

Siddharth P Sura  1 , Awais Ahmed, Adam S Cheifetz, Alan C Moss
Affiliations
Observational Study

Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis

Siddharth P Sura et al. J Clin Gastroenterol. 2014 Apr.

Abstract

Goals and background: Inflammatory bowel disease (IBD) serology testing is often used in patients with indeterminate colitis (IC) to help distinguish between ulcerative colitis (UC) and Crohn's disease (CD). We investigated the performance of serology testing in predicting future diagnosis in this setting.

Study: This was an observational study of individuals with IC at a single center who underwent IBD serology testing [anti-Saccharomyces cerevisiae antibody (ASCA), perinuclear anti-neutrophil cytoplasmic antibody (pANCA), and anti-outer membrane porin C antibody (anti-OmpC)] and had at least 12 months follow-up from the time of serology test results.

Results: A total of 117 individuals with IC and with 1-year follow-up data were enrolled. All IC patients had endoscopic and histologic evidence of colitis at enrollment. One year after serology testing, 58 (50%) individuals with IC were diagnosed with UC, 49 (42%) with CD, and 10 (9%) remained labeled with IC. The sensitivity/specificity of an initial positive pANCA for a subsequent diagnosis of UC was 78%/44%. For ASCA and anti-OmpC, the results were 18%/84% and 27%/75%, respectively, for a subsequent diagnosis of CD. A positive pANCA test was associated with a likelihood ratio (LR) of 1.4 [95% confidence interval (CI), 1.1-1.8] for a subsequent diagnosis of UC at 1 year. Neither positive ASCA (LR 1.1; 95% CI, 0.5-2.5) nor anti-OmpC (LR 1.1; 95% CI, 0.6-2.0) was associated with a subsequent diagnosis of CD in patients with IC.

Conclusions: The disease phenotype in the majority of individuals initially labeled with IC evolved to be more consistent with either UC or CD on follow-up. pANCA, ASCA, and anti-OmpC, individually, were of limited utility in predicting a patient's subsequent disease phenotype.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: ASC has served on advisory boards for Prometheus Laboratories Inc.

Figures

Figure 1
Figure 1
Negative (−) and positive (+) likelihood ratio (LR) for UC or CD diagnosis at 12 months following serology testing in patients with IC.
See this image and copyright information in PMC

Comment in

References

    1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. - PubMed
    1. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518–32. - PubMed
    1. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004;4:167–74. - PubMed
    1. Geboes K, Colombel JF, Greenstein A, et al. Indeterminate colitis: a review of the concept--what’s in a name? Inflamm Bowel Dis. 2008;14:850–857. - PubMed
    1. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease--’colitis indeterminate’. J Clin Pathol. 1978;31:567–77. - PMC - PubMed

Publication types

MeSH terms